Next Article in Journal
The Inverse Correlation of Isoflavone Dietary Intake and Headache in Peri- and Post-Menopausal Women
Next Article in Special Issue
Therapeutic Effects of a Novel Form of Biotin on Propionic Acid-Induced Autistic Features in Rats
Previous Article in Journal
The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004
Previous Article in Special Issue
Mineral Composition of Dietary Supplements-Analytical and Chemometric Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 14
Issue 6
10.3390/nu14061225
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer

by
Iwona J. Stanisławska
1,
Ramona Figat
2,
Anna K. Kiss
3 and
Barbara Bobrowska-Korczak
1,*
1
Department of Bromatology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
2
Department of Environmental Health Sciences, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
3
Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Nutrients 2022, 14(6), 1225; https://doi.org/10.3390/nu14061225
Submission received: 5 February 2022 / Revised: 9 March 2022 / Accepted: 11 March 2022 / Published: 14 March 2022
(This article belongs to the Special Issue Health Benefits of Micronutrients (Vitamins and Minerals) in Functional Products)
Browse Figures
Versions Notes

Abstract

:
The intake of selected minerals, especially zinc, calcium and selenium, and high consumption of dietary isoflavones are recognised as factors influencing prostate cancer risk. Moreover, changes in levels of some essential elements are characteristic of the disease. Here, we examined the combined effects of main dietary isoflavonoids (genistein, daidzein and its metabolite, equol) and minerals implicated in prostate cancer, namely zinc, selenium, copper, iron and calcium, on LNCaP prostate cancer cells proliferation. Secondly, we evaluated the influence of the combinations on genotoxicity of model mutagens, 4-nitroquinoline oxide (4NQO) and 2-aminoanthracene (2AA), in the umu test. All combinations of isoflavonoids and minerals inhibited prostate cancer cells growth. However, only mixtures with iron ions had significantly stronger effect than the phytochemicals. Interestingly, we observed that only genistein attenuated genotoxicity of 4NQO. The addition of any tested mineral abolished this effect. All tested isoflavonoids had anti-genotoxic activity against 2AA, which was significantly enhanced in the presence of copper sulphate. Our results indicate that the tested minerals in physiological concentrations had minimal influence on the anti-proliferative activity of isoflavonoids. However, they significantly modulated the anti-genotoxic effects of isoflavonoids against both metabolically activated and direct mutagens. Thus, the minerals intake and nutritional status may modulate protective action of isoflavonoids.

1. Introduction

Prostate cancer is the second most commonly diagnosed cancer and the fifth cause of cancer mortality in men worldwide. The GLOBOCAN database estimates 1.41 million new cases and 375,300 deaths from prostate cancer in 2020 [1]. Prostate cancer incidence and mortality rates, though rising, remain lowest in most Asian regions. Although the highest mortality rates are observed in countries with a significant population of African descent, in regions with the highest incidence rate, i.e., Australia and New Zealand, Northern and Western Europe and Northern America, prostate cancer is also a prominent cause of cancer death [2,3]. Distinct ethnic and geographic patterns of symptomatic disease incidence combined with lesser prevalence diversity of latent prostate cancer as well as studies on migrant populations brought attention to the influence of modifiable factors on prostate cancer risk [4,5,6]. A substantial number of them depend on dietary habits. The intake or nutritional status of selected nutrients as well as consumption of specific food products is linked with modulation of prostate cancer risk [5].
Soy food products, a major source of isoflavone phytoestrogens characteristic for traditional East and Southeast Asia cuisine, are among the dietary factors inversely associated with prostate cancer risk [5,7,8]. Soy isoflavones were shown to influence prostate cancer cells through numerous mechanisms in in vitro and in vivo studies and impact their proliferation and viability (reviewed in [9]). Moreover, soy isoflavones, especially genistein, exerted anti-genotoxic effects against direct and promutagens [10]. Some essential minerals were also indicated as factors influencing prostate health. High consumption of dairy and calcium is linked with increased risk of prostate cancer, whereas selenium intake is associated inversely with it [5]. Zinc is an element with a profound role in prostate gland function and pathology [11]. The results of epidemiological studies are often not conclusive [5] or even outright contradictory, as seen for calcium [12,13,14]. Moreover, changes in levels of several essential elements in serum and prostate tissue are associated with prostate cancer and may correlate with severity of the disease. Decreased levels of zinc and selenium as well as an increase in copper, iron and calcium levels are among the characteristics seen in prostate cancer patients [15,16,17]. However, it is difficult to determine whether changes in essential minerals levels are causal factors or markers/results of pathological process [13]. A direct effect of minerals level on prostate cancer cells was demonstrated in in vitro models for zinc [18,19,20], selenium [21,22,23], copper [24,25], iron [26] and calcium [27,28]. Some studies reported unfavourable results of minerals supplementation in culture medium [28,29]. Moreover, modulation of the genotoxic effect of (pro)mutagens by minerals is a described phenomenon [30]. Exposure of prostate cancer cells to minerals is natural in an in vivo setting. The influence of isoflavonoids depends on individual dietary habits and use of supplements [8]. Thus, the possibility of mutual modulation of the effects of isoflavonoids and minerals exists. However, to our knowledge such data are scarce and available to some extent only for mixtures of isoflavonoids and selenium compounds [31,32,33,34].
In this study, we evaluated the anti-proliferative, genotoxic and anti-genotoxic potential of dominant dietary isoflavones (genistein, daidzein and its microbiota metabolite equol) in combinations with selected minerals, and which tissue levels were implicated in prostate cancer development and progression. Significant modulation of anti-genotoxic effects of isoflavonoids by the tested minerals suggests that chemopreventive potential of dietary isoflavonoids may be modified by minerals balance or nutritional status. We used the LNCaP prostate cancer cell line, which is characterized by relative susceptibility to anti-proliferative effects of isoflavonoids in comparison to androgen-independent cell lines (e.g., DU-145, PC-3) [35,36,37,38,39], as model suitable for detection of both enhanced and attenuated effects of tested combinations.

2. Materials and Methods

2.1. Materials

LNCaP human prostate cancer cell line was obtained from ATCC (Manassas, VA, USA). Salmonella typhimurium strain TA1535/pSK1002 was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Inhoffenstraße 7B 38124 Braunschweig, Germany). DMEM medium supplemented with phenol red, Ultraglutamine and high glucose (4.5 g/L) was from Lonza (Verviers, Belgium). The solutions of penicillin/streptomycin, 0.25% trypsin-EDTA and phosphate buffered saline (PBS) were from Gibco (Paisley, UK). Genistein (≥98%, HPLC), daidzein (≥98%), equol (≥99%, TLC), fetal bovine serum (FBS), sodium pyruvate solution (100 mM), deoxyribonucleic acid sodium salt type XIV: from herring testes, bisbenzimide H 33258, camptothecin, 4-nitroquinoline N-oxide (4NQO), 2-aminoanthracene (2AA), d-glucose 6-phosphate disodium salt hydrate (G-6-P) and 2-nitrophenyl β-d-galactopyranoside (ONPG) were purchased from Sigma-Aldrich (Poznań, Poland). Nicotinamide adenine dinucleotide phosphate (NADP) was purchased from MP Biomedicals. Zinc sulphate (ZnSO4 × 7H2O, ≥99.5%), sodium selenate (Na2SeO4, ≥98%), copper(II)/cupric sulphate (CuSO4 × 5H2O, ≥99%), iron(II) sulphate (FeSO4 × 7H2O, ≥99%), DMSO were obtained from POCH (Gliwice, Poland) and calcium chloride (CaCl2 × 6H2O, ≥98%) was from Chempur (Piekary Śląskie, Poland). Methanol was purchased from Merck (Warsaw, Poland).

The Solutions Preparation

Stock solutions of isoflavones (genistein daidzein and equol), camptothecin, 4NQO and 2AA were prepared in sterile DMSO in aseptic conditions. The salts of tested elements (Zn, Se, Cu, Fe, Ca) were dissolved in deionised water (Merck Milipore, Darmstadt, Germany). The working solutions of elements were prepared by their dilution with 0.9% saline and filtration through 0.22 µM filter in aseptic conditions.

2.2. Assessment of the Effect on Human Prostate Cancer Cells Proliferation and Iability/Apoptosis

2.2.1. Cell Culture

LNCaP cells (passage 12–18) were maintained in DMEM medium supplemented with 10% (v/v) FBS, sodium pyruvate (1 mM), penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C in 5% CO2 humidified atmosphere.

2.2.2. Proliferation Studies

LNCaP cells (4–5 × 104/well) were seeded in 24-well plates and allowed to attach for 48 h and treated for the indicated time with Zn (0.5 μg/mL/7.6 μM), Se (30 ng/mL/0.38 μM), Cu (0.5 μg/mL/7.9 μM), Fe (1.5 μg/mL/26.9 μM), Ca (40 μg/mL/1 mM), 10 μM isoflavone (genistein, daidzein or equol) and the combinations of isoflavone with each element. The final concentration of DMSO was 0.05%. It must be noted that DMEM contains 1.8 mM of calcium. Thus, control cells were exposed to 1.8 mM (72 μg/mL) of the mineral, and Ca-treated cells to total concentration of 2.8 mM (112 μg/mL) calcium. The cells were then gently washed with 0.9% saline and lysed by brief sonication in deionised water. The cell proliferation was quantified by measurement of bisbenzimide H 33,258–DNA complexes fluorescence on Synergy 4 microplate reader with Gen5 software (BioTek Instruments Inc., 100 Tigan St, Winooski, VT 05404, USA) [40].

2.2.3. Fluorescent Imaging

LNCaP cells, treated with Se, Fe and genistein for 48 h, were stained for 1 h with Hoechst 33,258 dye added directly to the culture medium (final concentration 5 μg/mL). The images were recorded with the DS-Fi1 camera connected with Eclipse TS100F inverted microscope with Epi-Fluorescent attachment (DAPI filter) and NIS-Elements BR 2.3 software.

2.3. Anti-Genotoxicity Assessment

2.3.1. Umu-Test

The umu-test detects the induction of bacterial DNA-damage response, the SOS system, in the strain S. typhimurium TA1535/pSK1002. The test strain carries pSK1002 plasmid, which contains the fusion of umuC, encoding one of SOS response proteins, and lacZ genes. The expression of β-galactosidase protein is fully controlled by umuC gene. Thus, β-galactosidase activity illustrates the level of SOS response and the genotoxic potency of the tested compound [41,42].
In the present study, the umu-test was performed in the micro-plate format according to the ISO guideline [43]. The β-galactosidase activity was determined by the degree of ONPG cleavage measured as sample absorbance at 420 nm. The extent of SOS system activation was presented as induction ratio (IR), calculated as the ratio of β-galactosidase activity in the presence of the tested compound(s) to that of negative control. An IR value equal or greater than 1.5 indicated the genotoxic effect of the tested compound(s). The optical density at 600 nm was used to describe the bacteria growth. A growth ratio value higher than 0.5 relative to negative control indicated lack of growth inhibition. Both measurements were performed with Asys UVM340 Hightech microplate spectrophotometer.

2.3.2. Metabolic Activation

The S9 fraction from rat liver was used for metabolic activation of the tested compounds and the model mutagen. The male Sprague-Dawley rats were administered single dose of Aroclor 1254 (500 mg/kg b.w. in soybean oil) five days before S9 fraction isolation. The P450 cytochrome level in the isolate was evaluated and the aliquots were stored at −80 °C. The S9 reaction mix was prepared as described by Maron and Ames [44].

2.3.3. Determination of Anti-Genotoxicity by the Umu Test

In order to the establish anti-genotoxic potential of tested compounds, their effects on the action of two model genotoxic agents, 4NQO without the metabolic activation with rat liver S9 fraction and 2AA with metabolic activation, were evaluated. Firstly, the genotoxic potentials of 4NQO (0.05 and 0.25 μg/mL) and 2AA (1 and 10 μg/mL) were measured by the umu-test. Simultaneously, the genotoxicity of the tested isoflavones (10 μM), minerals (0.5 μg/mL Zn, 30 ng/mL Se, 0.5 μg/mL Cu, 1.5 μg/mL Fe, 40 μg/mL Ca) and their combinations was investigated. Subsequently, the modulation of 4NQO and 2AA genotoxicity by the isoflavones, the elements and their mixtures in previously used concentrations was investigated. The rate of anti-genotoxicity (%) of the tested sample was calculated as the inhibition of IR induced by the genotoxic agent (4NQO or 2AA) at the particular concentration according to the following formula:
Anti - genotoxicity % = ( 1 − IR genotoxin + sample IR genotoxin ) × 100 % .

2.4. Statistical Analysis

The data were obtained from at least three independent experiments performed in triplicate. Statistical significance was established using ANOVA and Dunnett’s and Tuckey’s post hoc tests. p values < 0.05 were considered significant. Data are presented as mean ± standard deviation (SD).

3. Results

3.1. Proliferation of LNCaP Cells

The supplementation of each mineral in culture medium moderately decreased LNCaP prostate cancer cells proliferation to 67–81% and 62–84% of control after 24 h and 48 h of incubation, respectively (p < 0.001) (Figure 1). In this in vitro assay, Fe had the most pronounced effect (38 ± 3% inhibition after 48 h), which was greater than those of other minerals (p < 0.001). There was no significant change in the minerals’ anti-proliferative effect with the extension of exposure time from 24 h to 48 h.
The isoflavonoids had similar anti-proliferative effect at 10 μM (16–28% of inhibition) after 24 h of incubation to the minerals. Contrary to the effect of the minerals, extension of incubation time to 48 h led to further decrease of proliferation by daidzein (84 ± 10% vs. 70 ± 7%, p < 0.01), equol (81 ± 9% vs. 60 ± 9%, p < 0.001) and genistein (72 ± 9 vs. 55 ± 9%, p = 0.001). Equol and genistein acted significantly stronger than Zn (82 ± 10%), Se (84 ± 11%), Cu (80 ± 14%) and Ca (80 ± 9%) after 48 h of incubation (p < 0.001).
The effects of the combinations of minerals with isoflavonoids were largely comparable to those of the respective isoflavonoids. The mixtures with Fe were the only ones which had improved anti-proliferative activity in comparison with daidzein (Figure 1A) and genistein (Figure 1C). The combination of Fe with equol showed a tendency to act stronger than the isoflavone metabolite (p ≤ 0.09, Figure 1B). However, no additive or synergistic effect was observed as effects of Fe and the Fe combinations with isoflavonoids did not differ significantly. Our observations indicate that the effects of tested isoflavonoid–mineral combinations were comparable to the effect of the more active constituent of given combination. We have seen no attenuation of the anti-proliferative effect.

3.2. Viability/Apoptosis of LNCaP Cells

We evaluated the effect of the most active isoflavone and mineral in the proliferation test, i.e., genistein and Fe, on the viability and apoptosis of LNCaP cells. The action of Se was also assessed based on significant associations of selenium levels and prostate cancer occurrence. As shown in Figure 2, genistein, Fe or Se used individually did not induce apoptosis in LNCaP cells. Neither the spindle shape nor the morphology of the cells were changed (Figure 2B,C,E) in comparison to control cells (Figure 2A). We did not observe increased amount of cells with condensed chromatin or apoptotic nuclei which was dyed bright blue with Hoechst stain in cells as seen for positive control—the camptothecin-treated cells (Figure 2g). Similarly, no such changes were observed in cells treated with a mixture of genistein and Fe (Figure 2F,f). However, some less adhered, rounded cells (Figure 2D) without marks of apoptosis (Figure 2d) were observed after treatment with combination of Se and genistein. Cells treated with genistein, minerals (Se, Fe) or their combinations show lightly dyed nuclei with uncondensed chromatin.

3.3. Anti-Genotoxicity Assessment

Neither the tested isoflavones nor the minerals showed genotoxic activity in the umu test (IR < 1.5) or inhibited the growth of bacteria (G > 0.5), irrespective of the metabolic activation (Table 1).
Genotoxicity of direct mutagen, 4-nitroquinoline oxide (4NQO), was significantly inhibited by genistein (20%), calcium (18%) and ferrous (20%) ions (Table 2), although only when a higher concentration (0.25 mg/L) of 4NQO was used. However, addition of any tested minerals, even those showing anti-genotoxic effect, abolished protective activity of genistein. Other isoflavonoids and minerals, either individually or in combination, had no effect on 4NQO genotoxicity (Table 2 and Table 3, graphical summary Table 4).
In the experiments with 2-aminoanthracen (2AA), a premutagen requiring metabolic activation by enzymes of S9 liver fraction, a significant decrease in its genotoxicity by genistein (by 17–32%), equol (29–34%) and daidzein (19%) was observed (Table 5 and Table 6). Genistein and equol had stronger anti-genotoxic effect against a lower concentration (1 mg/L) of 2AA, while daidzein activity was observed solely against higher concentration (5 mg/L) of 2AA. Ions of copper and iron were also able to attenuate 2AA genotoxicity by 26–33% and 14–21%, respectively (Table 5). The effects of both ions were more pronounced for a lesser concentration of premutagen.
Introduction of minerals modulated anti-genotoxic effects of isoflavonoids (graphic summary Table 7). Copper ions enhanced the effect of genistein (significance reached against 5 mg/L 2AA). Conversely, mixtures of genistein with zinc and selenate ions had attenuated anti-genotoxic effect in comparison to the isoflavone, especially against a lower concentration of 1 mg/L 2AA (Table 5).
The mixtures of daidzein with copper ions and, to a lesser extent, iron ions had significantly stronger anti-genotoxic activity against 2AA in comparison to daidzein. Although no statistical significance was reached, addition of zinc, calcium and selenate seemed to attenuate the action of daidzein (Table 6).
The mixtures of equol with copper and iron ions were more effective against 2AA genotoxicity than the isoflavonoid. The combination of equol with calcium ions had a contrary effect. Presence of zinc or selenate ions did not modulate the action of equol (Table 6).
It is worth noting that the effects of the mixtures containing copper ion were stronger than the effects of the respective isoflavone and copper ions used separately. The strongest anti-genotoxic effect (51% inhibition) was observed for the mixture of equol and copper ions. None of the tested isoflavones and minerals, either individually or in combination, increased the genotoxicity of model mutagens 4NQO and 2AA. Similarly, none of the used compounds or their mixtures were toxic to the bacteria (G > 0.5; Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 and Table 7).

4. Discussion

In this study, we examined the combined effects of selected essential elements (Zn, Se, Cu, Fe and Ca) and major dietary isoflavones—genistein, daidzein and its gut microbiota metabolite equol on hormone-dependent LNCaP prostate cancer cells and potency of model mutagens. The chosen concentrations of minerals were within the physiological range observed in human serum [12,15] and tissues [16,17]. Used concentrations of isoflavonoids corresponded to the maximal levels observed in prostatic tissue after soy isoflavones oral supplementation in doses achievable with high consumption of soy products [45].
We observed decreased proliferation in LNCaP cells in the presence of 10 μM tested isoflavones in accordance with the results of earlier studies [35,36,37,46]. Relative anti-proliferative activity of the isoflavones was also consistent with the reported pattern (genistein ≥ equol > daidzein) [46,47,48]. Genistein (10 μM) did not induce LNCaP cells apoptosis as described previously [9,37].
The supplementation of cell culture medium with tested minerals resulted only in a moderate decrease in cell proliferation. The tested minerals (Fe and Se) also did not induce apoptosis of prostate cancer cells. Although proapoptotic activity and decreased viability was described for iron and selenium compounds, it was observed at higher concentrations than used in the present study and, in the case of selenium, concerned selenite not selenate ions [21,22,26]. With the exception of iron, addition of essential elements did not significantly influence the effects of isoflavones. It is noteworthy that none of the isoflavone–mineral combinations had attenuated anti-proliferative effect. However, none of them showed stronger effect than the more active constituent of given mixture. With few exceptions such as selenium, the data on interactions between essential elements and isoflavones concerning prostate cancer are scarce.
Previous studies reported that inorganic zinc had strong inhibitory effect on LNCaP cells (IC50 = 100 ng/mL), induced apoptosis [18,19] and decreased PSA activity and LNCaP invasiveness [49]. Here the effects of zinc ions on growth of LNCaP cells were weaker, similarly to the recent work reporting increased degradation of AR protein in zinc-treated cells [20]. This discrepancy may be explained by differences in experimental design. The presence of serum in culture medium was a probable factor as it might modulate availability of zinc for the cells [50]. Both isoflavones and inorganic zinc are known to inhibit androgen receptor [20,51,52,53] and NF-κB signalling pathways [54,55]. There is evidence that several polyphenols modulate zinc distribution in prostatic cells [56]. Interaction with inorganic zinc was shown to sensitise cells to growth inhibition/cytotoxicity caused by epigallocatechin gallate [57] and paclitaxel [55]. No enhancement of anti-proliferative effect was observed for combinations of zinc and isoflavones in our study nor, to our knowledge, described in literature. However, isoflavones influenced zinc levels and expression of zinc transporters in prostate tissue in vivo [58].
Supplementation of inorganic selenium compounds in culture medium inhibited growth of prostate cancer cells [21,22]. Induction of apoptosis was also observed, albeit at higher concentrations than used in the present study (i.e., ≈380 nM) [22,23]. Contrarily, low concentrations of selenium, in form of selenite, were reported to stimulate repair of oxidative damage [59] and even LNCaP cells growth [60]. The combinations of genistein and selenite were previously shown to have enhanced growth inhibitory and pro-apoptotic effect on androgen dependent and independent prostate cancer cells [31,32]. Such phenomena were not observed in present study probably due to use of selenate (Se +6) rather than selenite (Se +4) and lower concentration of the compound in the mixture. Selenate had a significantly attenuated effect on prostate cancer cell growth and viability in comparison to selenite [21]. However, a few studies described a decrease in factors associated with prostate cancer risk in laboratory animals upon isoflavone and selenium supplementation [33,34].
Inorganic copper was noted to reduce prostate cancer cells (LNCaP and PC-3) proliferation at concentrations close to that used in the present study in accordance with our observations [24]. In another study, higher copper concentrations (≥100 μM) decreased the viability of PC-3 cells, but in the selected concentration range were shown to promote viability of HPV-immortalized RWPE-1 cells [25]. Copper ions were able to potentiate anti-cancer activity of compounds able to form copper chelates [61] and/or modulate oxidative stress in cells [24,62]. Similarly, iron ions (200 µM) decreased proliferation and viability of prostate cancer cells, albeit ferric ions were reported to have lower activity than that of ferrous ions seen in present study, i.e., the decrease did not reach significance for concentrations 10–100 μM [26]. It is worth noting that iron supplementation enhanced anti-cancer effects of clinically used anti-androgen, bicalutamide, through exacerbation of oxidative stress in vitro and in vivo [26]. However, it is a delicate balance as lower concentrations of ferric ions (100 µM) were seen to increase the invasiveness of prostate cancer cells in a redox-dependent mechanism [29].
Here, we did not observe significant potentiation of the anti-proliferative effect of isoflavones combinations with copper or iron ions in comparison to the effects of both mixture components used individually. As described in the works cited above, oxidative stress is important mechanism of copper and iron cytotoxicity. Metal ions interact with flavonoids, including isoflavones, forming chelates and/or changing oxidation state [63], which may contribute to the modulation of their biological activity [56,64], e.g., epigallocatechin gallate with copper and zinc ions [24,57]. In contrast to some other flavonoids, isoflavones are able to reduce cupric to cuprous ions but not ferric to ferrous ions. Moreover, isoflavones are rather weak chelators among flavonoids and taking into account relative concentrations used in this study formation of both iron and copper chelates with isoflavones seems unlikely [63,65].
Calcium is a macromineral with vital role in cells function and its altered signalling, through various mechanisms, is implicated in prostate cancer [66]. The effects of extracellular calcium levels are not clear [5]. It must be noted that in serum calcium levels are under tight homeostatic control [67]. Epidemiological studies report that higher serum calcium levels are associated with increased [12], unchanged [13] or decreased [14,68] prostate cancer risk. Elevated concentrations of extracellular calcium promoted growth of prostate cancer cells derived from bone metastases [27,28]. The prostate cells not derived from bone metastases did not react to increased extracellular calcium levels from 0.5 (indicative of severe hypocalcaemia in vivo) to 2.5 mM [28]. We observed a slight but significant decrease in proliferation in LNCaP cells derived from lymph node metastases in response to an increase in calcium concentration from 1.8 to 2.8 mM.
The prevention of DNA changes caused by chemical, physical or biologic factors is among main mechanisms of chemoprevention [69]. Thus, we explored the effects of isoflavones, minerals and their combinations on activity of model mutagens, direct genotoxin 4NQO and promutagen 2AA. As expected, isoflavones did not show genotoxicity and exerted protective effect against direct (only genistein) and indirect mutagens in an umu test [10,70,71,72]. Isoflavonoids are able to inhibit numerous microsomal enzymes [73], which may to some extent explain their protective effect against metabolically activated promutagen. Anti-genotoxicity assessment showed consistent enhancement of isoflavonoids activity against 2AA-induced mutagenesis in the presence of cupric ions. Such effect was not seen in tests against 4NQO, where metal ions abolished protective effects of genistein. Copper ions demonstrated ability to increase mutagenicity of 4NQO and to reduce mutagenicity of S9 activated 2AA in S. typhimurium revertant test [30], albeit at much higher concentration than used here. Although there was report describing increased radical scavenging activity of genstein-cupric ion complex [74], such interaction with daidzein and equol is impossible due to lack of 4-oxo–5-hydroxy chelating site [63]. Thus, the effect observed here may be caused by modulation of isoflavonoids interaction with S9 fraction enzymes in the presence of cupric ion.
Prostate cancer is characterised by a long latency period preceding occurrence of symptomatic disease, which makes it a suitable target for preventative interventions, e.g., through dietary means. Use of isoflavonoids and minerals supplements is popular in Western societies [75,76,77]. Our preliminary results tentatively indicate that combining selected minerals, e.g., copper with isoflavonoids may offer some increased protection against environmental promutagens. Combining achievable in vivo concentrations of isoflavonoids and selected minerals (Zn, Se, Cu, Fe, Ca) did not result in direct enhancement of activity against hormone-dependent prostate cancer cells. However, protection against the effects of environmental threats such as (pro)mutagens is an important aspect of chemoprevention [69]. Thus, significant modulation of isoflavonoids anti-genotoxic activity by the minerals indicates that minerals nutritional status and metabolic balance may be among the factors influencing individual protective potential of isoflavonoid exposure.

5. Conclusions

In conclusion, the current study shows that the tested minerals in physiological concentrations have minimal influence on the anti-proliferative activity of isoflavonoids. However, they significantly modulate the anti-genotoxic effects of isoflavonoids against both metabolically activated and direct mutagens. Thus, the minerals intake and nutritional status may modulate protective action of isoflavonoids.

Author Contributions

Conceptualization, B.B.-K. and A.K.K.; formal analysis, I.J.S. and R.F.; investigation, I.J.S. and R.F.; resources, A.K.K., B.B.-K. and R.F.; writing—original draft preparation, I.J.S.; writing—review and editing, I.J.S., A.K.K. and B.B.-K.; visualization, I.J.S. and R.F.; supervision, B.B.-K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer 2021, 149, 778–789. [Google Scholar] [CrossRef] [PubMed]
  3. Culp, M.B.; Soerjomataram, I.; Efstathiou, J.A.; Bray, F.; Jemal, A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur. Urol. 2020, 77, 38–52. [Google Scholar] [CrossRef]
  4. Kimura, T.; Egawa, S. Epidemiology of prostate cancer in Asian countries. Int. J. Urol. 2018, 25, 524–531. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Wilson, K.M.; Mucci, L.A. Diet and Lifestyle in Prostate Cancer. In Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression; Dehm, S.M., Tindall, D.J., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 1–27. [Google Scholar] [CrossRef]
  6. Kimura, T.; Sato, S.; Takahashi, H.; Egawa, S. Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers 2021, 13, 359. [Google Scholar] [CrossRef] [PubMed]
  7. Applegate, C.C.; Rowles, J.L.; Ranard, K.M.; Jeon, S.; Erdman, J.W. Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Nutrients 2018, 10, 40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T. Isoflavones. Molecules 2019, 24, 1076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Mahmoud, A.M.; Yang, W.; Bosland, M.C. Soy isoflavones and prostate cancer: A review of molecular mechanisms. J. Steroid Biochem. Mol. Biol. 2014, 140, 116–132. [Google Scholar] [CrossRef] [Green Version]
  10. Lepri, S.R.; Luiz, R.C.; Zanelatto, L.C.; da Silva, P.B.; Sartori, D.; Ribeiro, L.R.; Mantovani, M.S. Chemoprotective activity of the isoflavones, genistein and daidzein on mutagenicity induced by direct and indirect mutagens in cultured HTC cells. Cytotechnology 2013, 65, 213–222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Costello, L.C.; Franklin, R.B. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch. Biochem. Biophys. 2016, 611, 100–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Skinner, H.G.; Schwartz, G.G. A Prospective Study of Total and Ionized Serum Calcium and Fatal Prostate Cancer. Cancer Epidemiol. Biomark. Prev. 2009, 18, 575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Van Hemelrijck, M.; Hermans, R.; Michaelsson, K.; Melvin, J.; Garmo, H.; Hammar, N.; Jungner, I.; Walldius, G.; Holmberg, L. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2012, 23, 1349–1358. [Google Scholar] [CrossRef]
  14. Salem, S.; Hosseini, M.; Allameh, F.; Babakoohi, S.; Mehrsai, A.; Pourmand, G. Serum Calcium Concentration and Prostate Cancer Risk: A Multicenter Study. Nutr. Cancer 2013, 65, 961–968. [Google Scholar] [CrossRef]
  15. Saleh, S.A.K.; Adly, H.M.; Abdelkhaliq, A.A.; Nassir, A.M. Serum Levels of Selenium, Zinc, Copper, Manganese, and Iron in Prostate Cancer Patients. Curr. Urol. 2020, 14, 44–49. [Google Scholar] [CrossRef]
  16. Sapota, A.; Daragó, A.; Taczalski, J.; Kilanowicz, A. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions. BioMetals 2009, 22, 1041. [Google Scholar] [CrossRef] [PubMed]
  17. Singh, B.P.; Dwivedi, S.; Dhakad, U.; Murthy, R.C.; Choubey, V.K.; Goel, A.; Sankhwar, S.N. Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer. Indian J. Clin. Biochem. 2016, 31, 50–56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Feng, P.; Liang, J.Y.; Li, T.L.; Guan, Z.X.; Zou, J.; Franklin, R.; Costello, L.C. Zinc induces mitochondria apoptogenesis in prostate cells. Mol. Urol. 2000, 4, 31–36. [Google Scholar] [PubMed]
  19. Liang, J.Y.; Liu, Y.Y.; Zou, J.; Franklin, R.B.; Costello, L.C.; Feng, P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999, 40, 200–207. [Google Scholar] [CrossRef] [Green Version]
  20. To, P.K.; Do, M.-H.; Cho, Y.-S.; Kwon, S.-Y.; Kim, M.S.; Jung, C. Zinc Inhibits Expression of Androgen Receptor to Suppress Growth of Prostate Cancer Cells. Int. J. Mol. Sci. 2018, 19, 3062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Rebsch, C.M.; Penna, F.J., 3rd; Copeland, P.R. Selenoprotein expression is regulated at multiple levels in prostate cells. Cell Res. 2006, 16, 940–948. [Google Scholar] [CrossRef] [Green Version]
  22. Zhong, W.; Oberley, T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res. 2001, 61, 7071–7078. [Google Scholar]
  23. Xiang, N.; Zhao, R.; Zhong, W. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemother. Pharmacol. 2009, 63, 351–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Yu, H.N.; Yin, J.J.; Shen, S.R. Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu2+. J. Agric. Food Chem. 2004, 52, 462–466. [Google Scholar] [CrossRef] [PubMed]
  25. Meng, H.Z.; Ni, X.F.; Yu, H.N.; Wang, S.S.; Shen, S.R. Effects of astaxanthin on oxidative stress induced by Cu(2+) in prostate cells. J. Zhejiang Univ. Sci. B 2017, 18, 161–171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Bordini, J.; Morisi, F.; Elia, A.R.; Santambrogio, P.; Pagani, A.; Cucchiara, V.; Ghia, P.; Bellone, M.; Briganti, A.; Camaschella, C.; et al. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. Clin. Cancer Res. 2020, 26, 6387–6398. [Google Scholar] [CrossRef] [PubMed]
  27. Bernichtein, S.; Pigat, N.; Barry Delongchamps, N.; Boutillon, F.; Verkarre, V.; Camparo, P.; Reyes-Gomez, E.; Mejean, A.; Oudard, S.M.; Lepicard, E.M.; et al. Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. Cancer Res. 2017, 77, 355–365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Liao, J.; Schneider, A.; Datta, N.S.; McCauley, L.K. Extracellular Calcium as a Candidate Mediator of Prostate Cancer Skeletal Metastasis. Cancer Res. 2006, 66, 9065–9073. [Google Scholar] [CrossRef] [Green Version]
  29. Guo, W.; Schlicht, M.; Kucynda, T.; Zhou, P.; Valyi-Nagy, K.; Kajdacsy-Balla, A. Abstract 4322: Iron increases the invasiveness of prostate cancer cells in vitro: Mechanisms and inhibition by the antioxidant ebselen. Cancer Res. 2012, 72, 4322. [Google Scholar] [CrossRef]
  30. Fujii, N.; Yano, S.; Takeshita, K. Selective enhancing effect of metal ions on mutagenicity. Gene Environ. 2016, 38, 21. [Google Scholar] [CrossRef] [Green Version]
  31. Kumi-Diaka, J.; Merchant, K.; Haces, A.; Hormann, V.; Johnson, M. Genistein-selenium combination induces growth arrest in prostate cancer cells. J. Med. Food 2010, 13, 842–850. [Google Scholar] [CrossRef]
  32. Zhao, R.; Xiang, N.; Domann, F.E.; Zhong, W. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr. Cancer 2009, 61, 397–407. [Google Scholar] [CrossRef] [Green Version]
  33. Legg, R.L.; Tolman, J.R.; Lovinger, C.T.; Lephart, E.D.; Setchell, K.D.; Christensen, M.J. Diets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostate. Reprod. Biol. Endocrinol. 2008, 6, 57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Tolman, J.R.; Lephart, E.D.; Setchell, K.D.; Eggett, D.L.; Christensen, M.J. Timing of supplementation of selenium and isoflavones determines prostate cancer risk factor reduction in rats. Nutr. Metab. 2008, 5, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Magee, P.J.; Raschke, M.; Steiner, C.; Duffin, J.G.; Pool-Zobel, B.L.; Jokela, T.; Wahala, K.; Rowland, I.R. Equol: A comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr. Cancer 2006, 54, 232–242. [Google Scholar] [CrossRef]
  36. Suzuki, K.; Koike, H.; Matsui, H.; Ono, Y.; Hasumi, M.; Nakazato, H.; Okugi, H.; Sekine, Y.; Oki, K.; Ito, K.; et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int. J. Cancer 2002, 99, 846–852. [Google Scholar] [CrossRef] [PubMed]
  37. Shen, J.C.; Klein, R.D.; Wei, Q.; Guan, Y.; Contois, J.H.; Wang, T.T.; Chang, S.; Hursting, S.D. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol. Carcinog. 2000, 29, 92–102. [Google Scholar] [CrossRef]
  38. Fan, Y.-J.; Huang, N.-S.; Xia, L. Genistein synergizes with RNA interference inhibiting survivin for inducing DU-145 of prostate cancer cells to apoptosis. Cancer Lett. 2009, 284, 189–197. [Google Scholar] [CrossRef]
  39. Chiyomaru, T.; Yamamura, S.; Fukuhara, S.; Yoshino, H.; Kinoshita, T.; Majid, S.; Saini, S.; Chang, I.; Tanaka, Y.; Enokida, H.; et al. Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR. PLoS ONE 2013, 8, e70372. [Google Scholar] [CrossRef]
  40. Kiss, A.; Kowalski, J.; Melzig, M.F. Induction of neutral endopeptidase activity in PC-3 cells by an aqueous extract of Epilobium angustifolium L. and oenothein B. Phytomedicine 2006, 13, 284–289. [Google Scholar] [CrossRef] [PubMed]
  41. Oda, Y.; Nakamura, S.; Oki, I.; Kato, T.; Shinagawa, H. Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat. Res. 1985, 147, 219–229. [Google Scholar] [CrossRef]
  42. Reifferscheid, G.; Heil, J.; Oda, Y.; Zahn, R.K. A microplate version of the SOS/umu-test for rapid detection of genotoxins and genotoxic potentials of environmental samples. Mutat. Res. 1991, 253, 215–222. [Google Scholar] [CrossRef]
  43. ISO 13829:2000; Water Quality—Determination of the Genotoxicity of Water and Waste Water Using the umu-Test. ISO: Geneva, Switzerland, 2000.
  44. Maron, D.M.; Ames, B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113, 173–215. [Google Scholar] [CrossRef]
  45. Gardner, C.D.; Oelrich, B.; Liu, J.P.; Feldman, D.; Franke, A.A.; Brooks, J.D. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate 2009, 69, 719–726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Raschke, M.; Wähälä, K.; Pool-Zobel, B.L. Reduced isoflavone metabolites formed by the human gut microflora suppress growth but do not affect DNA integrity of human prostate cancer cells. Br. J. Nutr. 2006, 96, 426–434. [Google Scholar] [CrossRef]
  47. Hedlund, T.E.; van Bokhoven, A.; Johannes, W.U.; Nordeen, S.K.; Ogden, L.G. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2006, 66, 557–566. [Google Scholar] [CrossRef] [PubMed]
  48. Hedlund, T.E.; Johannes, W.U.; Miller, G.J. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003, 54, 68–78. [Google Scholar] [CrossRef]
  49. Ishii, K.; Otsuka, T.; Iguchi, K.; Usui, S.; Yamamoto, H.; Sugimura, Y.; Yoshikawa, K.; Hayward, S.W.; Hirano, K. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 2004, 207, 79–87. [Google Scholar] [CrossRef] [PubMed]
  50. Costello, L.C.; Fenselau, C.C.; Franklin, R.B. Evidence for operation of the direct zinc ligand exchange mechanism for trafficking, transport, and reactivity of zinc in mammalian cells. J. Inorg. Biochem. 2011, 105, 589–599. [Google Scholar] [CrossRef] [Green Version]
  51. Bektic, J.; Berger, A.P.; Pfeil, K.; Dobler, G.; Bartsch, G.; Klocker, H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur. Urol. 2004, 45, 245–251. [Google Scholar] [CrossRef] [PubMed]
  52. Takahashi, Y.; Hursting, S.D.; Perkins, S.N.; Wang, T.C.; Wang, T.T. Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol. Carcinog. 2006, 45, 18–25. [Google Scholar] [CrossRef] [PubMed]
  53. Itsumi, M.; Shiota, M.; Takeuchi, A.; Kashiwagi, E.; Inokuchi, J.; Tatsugami, K.; Kajioka, S.; Uchiumi, T.; Naito, S.; Eto, M.; et al. Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Sci. 2016, 107, 1022–1028. [Google Scholar] [CrossRef]
  54. Davis, J.N.; Kucuk, O.; Sarkar, F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr. Cancer 1999, 35, 167–174. [Google Scholar] [CrossRef]
  55. Uzzo, R.G.; Leavis, P.; Hatch, W.; Gabai, V.L.; Dulin, N.; Zvartau, N.; Kolenko, V.M. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. 2002, 8, 3579–3583. [Google Scholar]
  56. Singh, C.K.; Chhabra, G.; Patel, A.; Chang, H.; Ahmad, N. Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management. Nutrients 2021, 13, 1867. [Google Scholar] [CrossRef]
  57. Yang, J.G.; Yu, H.N.; Sun, S.L.; Zhang, L.C.; He, G.Q.; Das, U.N.; Ruan, H.; Shen, S.R. Epigallocatechin-3-gallate affects the growth of LNCaP cells via membrane fluidity and distribution of cellular zinc. J. Zhejiang Univ. Sci. B 2009, 10, 411–421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Mohamad, J.; Masrudin, S.S.; Alias, Z.; Muhamad, N.A. The effects of Pueraria mirifica extract, diadzein and genistein in testosterone-induced prostate hyperplasia in male Sprague Dawley rats. Mol. Biol. Rep. 2019, 46, 1855–1871. [Google Scholar] [CrossRef] [PubMed]
  59. De Rosa, V.; Erkekoglu, P.; Forestier, A.; Favier, A.; Hincal, F.; Diamond, A.M.; Douki, T.; Rachidi, W. Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells. Free Radic. Res. 2012, 46, 105–116. [Google Scholar] [CrossRef]
  60. Kandas, N.O.; Randolph, C.; Bosland, M.C. Differential effects of selenium on benign and malignant prostate epithelial cells: Stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr. Cancer 2009, 61, 251–264. [Google Scholar] [CrossRef] [Green Version]
  61. Safi, R.; Nelson, E.R.; Chitneni, S.K.; Franz, K.J.; George, D.J.; Zalutsky, M.R.; McDonnell, D.P. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014, 74, 5819–5831. [Google Scholar] [CrossRef] [Green Version]
  62. Yu, H.N.; Shen, S.R.; Xiong, Y.K. Cytotoxicity of epigallocatechin-3-gallate to LNCaP cells in the presence of Cu2+. J. Zhejiang Univ. Sci. B 2005, 6, 125–131. [Google Scholar] [CrossRef] [Green Version]
  63. Mira, L.; Fernandez, M.T.; Santos, M.; Rocha, R.; Florencio, M.H.; Jennings, K.R. Interactions of flavonoids with iron and copper ions: A mechanism for their antioxidant activity. Free Radic. Res. 2002, 36, 1199–1208. [Google Scholar] [CrossRef]
  64. Chen, X.; Tang, L.-J.; Sun, Y.-N.; Qiu, P.-H.; Liang, G. Syntheses, characterization and antitumor activities of transition metal complexes with isoflavone. J. Inorg. Biochem. 2010, 104, 379–384. [Google Scholar] [CrossRef]
  65. Karlíčková, J.; Macáková, K.; Říha, M.; Pinheiro, L.M.; Filipský, T.; Horňasová, V.; Hrdina, R.; Mladěnka, P. Isoflavones Reduce Copper with Minimal Impact on Iron In Vitro. Oxidative Med. Cell. Longev. 2015, 2015, 437381. [Google Scholar] [CrossRef] [Green Version]
  66. Ardura, J.A.; Alvarez-Carrion, L.; Gutierrez-Rojas, I.; Alonso, V. Role of Calcium Signaling in Prostate Cancer Progression: Effects on Cancer Hallmarks and Bone Metastatic Mechanisms. Cancers 2020, 12, 1071. [Google Scholar] [CrossRef]
  67. Goldstein, D.A. Serum Calcium. In Clinical Methods: The History, Physical, and Laboratory Examinations, 3rd ed.; Walker, H.K., Hall, W.D., Hurst, J.W., Eds.; Butterworths: Boston, MA, USA, 1990; pp. 677–679. Available online: https://www.ncbi.nlm.nih.gov/books/NBK250/ (accessed on 1 January 2022).
  68. Halthur, C.; Johansson, A.L.V.; Almquist, M.; Malm, J.; Grönberg, H.; Manjer, J.; Dickman, P.W. Serum calcium and the risk of prostate cancer. Cancer Causes Control 2009, 20, 1205–1214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Melo, F.H.M.D.; Oliveira, J.S.; Sartorelli, V.O.B.; Montor, W.R. Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? Front. Oncol. 2018, 8, 644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Klein, C.B.; King, A.A. Genistein genotoxicity: Critical considerations of in vitro exposure dose. Toxicol. Appl. Pharmacol. 2007, 224, 1–11. [Google Scholar] [CrossRef] [PubMed]
  71. Di Virgilio, A.L.; Iwami, K.; Wätjen, W.; Kahl, R.; Degen, G.H. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicol. Lett. 2004, 151, 151–162. [Google Scholar] [CrossRef]
  72. Schwen, R.; Jackson, R.; Proudlock, R. Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests. Food Chem. Toxicol. 2010, 48, 3481–3485. [Google Scholar] [CrossRef]
  73. Kopečná-Zapletalová, M.; Krasulová, K.; Anzenbacher, P.; Hodek, P.; Anzenbacherová, E. Interaction of isoflavonoids with human liver microsomal cytochromes P450: Inhibition of CYP enzyme activities. Xenobiotica 2017, 47, 324–331. [Google Scholar] [CrossRef] [PubMed]
  74. Dowling, S.; Regan, F.; Hughes, H. The characterisation of structural and antioxidant properties of isoflavone metal chelates. J. Inorg. Biochem. 2010, 104, 1091–1098. [Google Scholar] [CrossRef] [PubMed]
  75. Jazieh, A.R.; Kopp, M.; Foraida, M.; Ghouse, M.; Khalil, M.; Savidge, M.; Sethuraman, G. The use of dietary supplements by veterans with cancer. J. Altern. Complement. Med. 2004, 10, 560–564. [Google Scholar] [CrossRef] [PubMed]
  76. Rock, C.L. Multivitamin-multimineral supplements: Who uses them? Am. J. Clin. Nutr. 2007, 85, 277–279. [Google Scholar] [CrossRef] [Green Version]
  77. Velicer, C.M.; Ulrich, C.M. Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J. Clin. Oncol. 2008, 26, 665–673. [Google Scholar] [CrossRef]
Nutrients 14 01225 g001 550
Figure 1. The anti-proliferative effects of (micro)elements and isoflavones on LNCaP cells. The solid bars represent the effects of single agents and the patterned bars the effects of combinations of (A) daidzein (dai), (B) equol (eq) and (C) genistein (gen) with designated elements. * p < 0.05, *** p < 0.001 vs. control; # p < 0.05, ## p < 0.01 vs. 10 μM isoflavone; $ p < 0.05, $$$ p < 0.001 vs. respective element.
Figure 1. The anti-proliferative effects of (micro)elements and isoflavones on LNCaP cells. The solid bars represent the effects of single agents and the patterned bars the effects of combinations of (A) daidzein (dai), (B) equol (eq) and (C) genistein (gen) with designated elements. * p < 0.05, *** p < 0.001 vs. control; # p < 0.05, ## p < 0.01 vs. 10 μM isoflavone; $ p < 0.05, $$$ p < 0.001 vs. respective element.
Nutrients 14 01225 g001
Nutrients 14 01225 g002 550
Figure 2. The effect of genistein, selenium and iron on LNCaP cells viability. The representative photographs of LNCaP cells: control (A,a), treated with genistein (B,b), selenium (C,c), iron (E,e) and combinations of genistein with Se (D,d) and Fe (F,f). The cells treated with 2 µM camptothecin (G,g) were positive control. Scale bar–100 µm. Photographs marked with uppercase letters present cells morphology. Photographs marked with lowercase letters show the fluorescence of Hoechst 33,258 stained cells.
Figure 2. The effect of genistein, selenium and iron on LNCaP cells viability. The representative photographs of LNCaP cells: control (A,a), treated with genistein (B,b), selenium (C,c), iron (E,e) and combinations of genistein with Se (D,d) and Fe (F,f). The cells treated with 2 µM camptothecin (G,g) were positive control. Scale bar–100 µm. Photographs marked with uppercase letters present cells morphology. Photographs marked with lowercase letters show the fluorescence of Hoechst 33,258 stained cells.
Nutrients 14 01225 g002
Table
Table 1. Genotoxicity assessment—the values of growth (G) and induction (IR) ratios for the tested compounds and their combinations with (+S9) and without metabolic activation (−S9).
Table 1. Genotoxicity assessment—the values of growth (G) and induction (IR) ratios for the tested compounds and their combinations with (+S9) and without metabolic activation (−S9).
Tested Mixture+S9−S9
G
(Mean ± SD)		IR
(Mean ± SD)		G
(Mean ± SD)		IR
(Mean ± SD)
Negative Control1.00 ± 0.071.00 ± 0.131.00 ± 0.061.00 ± 0.13
gen1.16 ± 0.170.78 ± 0.161.28 ± 0.350.75 ± 0.15
Zn1.04 ± 0.050.99 ± 0.161.09 ± 0.131.02 ± 0.24
Cu1.07 ± 0.110.93 ± 0.111.09 ± 0.120.87 ± 0.17
Ca1.09 ± 0.150.99 ± 0.121.11 ± 0.090.93 ± 0.19
Se1.09 ± 0.130.98 ± 0.151.14 ± 0.110.92 ± 0.19
Fe0.98 ± 0.100.97 ± 0.101.10 ± 0.100.90 ± 0.19
gen + Zn1.03 ± 0.151.03 ± 0.211.18 ± 0.420.80 ± 0.23
gen + Cu0.99 ± 0.111.03 ± 0.190.88 ± 0.091.01 ± 0.21
gen + Ca1.03 ± 0.081.02 ± 0.191.13 ± 0.140.86 ± 0.13
gen + Se1.04 ± 0.111.05 ± 0.141.00 ± 0.101.03 ± 0.24
gen + Fe1.06 ± 0.071.03 ± 0.131.03 ± 0.091.04 ± 0.16
dai0.94 ± 0.120.98 ± 0.131.25 ± 0.280.86 ± 0.14
dai + Zn0.92 ± 0.101.06 ± 0.181.05 ± 0.081.03 ± 0.17
dai + Cu1.00 ± 0.131.10 ± 0.131.11 ± 0.151.02 ± 0.17
dai + Ca1.02 ± 0.120.95 ± 0.111.12 ± 0.150.97 ± 0.10
dai + Se1.06 ± 0.071.02 ± 0.071.14 ± 0.111.03 ± 0.12
dai + Fe1.03 ± 0.080.99 ± 0.081.07 ± 0.110.87 ± 0.16
eq1.06 ± 0.090.84 ± 0.101.18 ± 0.330.83 ± 0.16
eq + Zn1.04 ± 0.100.91 ± 0.110.89 ± 0.141.24 ± 0.33
eq + Cu1.10 ± 0.070.90 ± 0.120.99 ± 0.141.31 ± 0.52
eq + Ca1.10 ± 0.100.92 ± 0.130.98 ± 0.071.04 ± 0.18
eq + Se1.14 ± 0.100.98 ± 0.141.07 ± 0.071.23 ± 0.30
eq + Fe1.05 ± 0.070.93 ± 0.131.02 ± 0.081.15 ± 0.50
Each value is expressed as mean ± standard deviation from at least 3 independent biological evaluation.
Table
Table 2. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—4NQO (4-nitroquinoline oxide) (0.25 mg/L, 0.05 mg/L)—and the mixture of NQO with genistein, minerals and their combinations.
Table 2. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—4NQO (4-nitroquinoline oxide) (0.25 mg/L, 0.05 mg/L)—and the mixture of NQO with genistein, minerals and their combinations.
Tested MixtureG
(Mean ± SD)		IR
(Mean ± SD)		%Anti-Genotox.
Negative Control1.00 ± 0.061.00 ± 0.13
NQO 0.25 mg/L0.95 ± 0.116.06 ± 1.48
gen1.12 ± 0.244.84 ± 1.4720%
Zn1.01 ± 0.115.20 ± 1.44
Cu1.00 ± 0.125.14 ± 1.41
Ca1.11 ± 0.054.94 ± 1.2818%
Se1.11 ± 0.055.19 ± 1.63
Fe1.08 ± 0.104.86 ± 1.2720%
gen + Zn0.98 ± 0.185.95 ± 1.24 a
gen + Cu0.85 ± 0.096.26 ± 0.84 a
gen + Ca1.01 ± 0.095.52 ± 0.58 a
gen + Se0.95 ± 0.095.98 ± 0.89 a
gen + Fe0.99 ± 0.075.50 ± 0.51 a
NQO 0.05 mg/L0.99 ± 0.102.64 ± 0.63
gen1.01 ± 0.122.48 ± 0.58
Zn1.01 ± 0.112.36 ± 0.46
Cu0.98 ± 0.102.42 ± 0.61
Ca1.13 ± 0.082.22 ± 0.54
Se1.10 ± 0.092.39 ± 0.48
Fe1.10 ± 0.102.24 ± 0.52
gen + Zn0.89 ± 0.112.77 ± 0.78
gen + Cu0.78 ± 0.063.04 ± 0.79
gen + Ca1.00 ± 0.112.55 ± 0.45
gen + Se0.97 ± 0.072.74 ± 0.53
gen + Fe1.04 ± 0.092.56 ± 0.34
Each value is expressed as mean ± standard deviation from at least 3 independent biological evaluations. Means that are significant different from positive control (2AA) are bolded (p < 0.05). a Significantly different from the effect of genistein (10 μM) without minerals. %anti-genotox. of the tested samples is calculated as the inhibition of IR induced by genotoxin (4NQO).
Table
Table 3. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—4NQO (0.25 mg/L, 0.05 mg/L)—and the mixture of NQO with daidzein, equol and the combinations with minerals.
Table 3. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—4NQO (0.25 mg/L, 0.05 mg/L)—and the mixture of NQO with daidzein, equol and the combinations with minerals.
Tested MixtureG
(Mean ± SD)		IR
(Mean ± SD)		%Anti-Genotox.
Negative Control1.00 ± 0.091.00 ± 0.16
NQO 0.25 mg/L0.78 ± 0.129.92 ± 3.06
Dai1.03 ± 0.257.92 ± 2.64
dai + Zn0.93 ± 0.108.57 ± 2.50
dai + Cu0.99 ± 0.149.23 ± 2.76
dai + Ca1.06 ± 0.218.60 ± 2.87
dai + Se1.09 ± 0.208.67 ± 2.57
dai + Fe1.04 ± 0.208.06 ± 2.47-
Eq0.97 ± 0.269.25 ± 4.77
eq + Zn0.80 ± 0.1610.49 ± 3.87
eq + Cu0.84 ± 0.119.67 ± 2.86
eq + Ca0.90 ± 0.199.64 ± 3.62
eq + Se0.96 ± 0.159.36 ± 2.56
eq + Fe0.90 ± 0.148.37 ± 2.58
NQO 0.05 mg/L0.97 ± 0.152.80 ± 1.56
Dai0.94 ± 0.162.48 ± 1.65
dai + Zn0.86 ± 0.102.78 ± 1.87
dai + Cu0.92 ± 0.142.70 ± 1.53
dai + Ca1.06 ± 0.182.54 ± 1.37
dai + Se1.12 ± 0.152.54 ± 1.36
dai + Fe1.09 ± 0.162.36 ± 1.11-
Eq1.06 ± 0.272.75 ± 1.63
eq + Zn0.89 ± 0.133.25 ± 2.03
eq + Cu0.96 ± 0.113.07 ± 1.49
eq + Ca1.04 ± 0.082.82 ± 1.39
eq + Se1.03 ± 0.113.17 ± 1.73
eq + Fe0.95 ± 0.102.80 ± 1.37
Each value is expressed as mean ± standard deviation from at least 3 independent biological evaluations.
Table
Table 4. Summary of anti-genotoxic activity of isoflavonoids, minerals and their combinations against direct mutagen 4NQO (0.25 mg/L; 0.05 mg/L).
Table 4. Summary of anti-genotoxic activity of isoflavonoids, minerals and their combinations against direct mutagen 4NQO (0.25 mg/L; 0.05 mg/L).
Nutrients 14 01225 i001
+—anti-genotoxicty of used compound(s) ≤ 20%. Red colour—significant attenuation of anti-genotoxic activity of isoflavonoid (p > 0.05); gen—genistein; dai—daidzein; eq—equol.
Table
Table 5. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—2AA (5 mg/L, 1 mg/L)—and the mixture of 2AA with genistein, minerals and combinations.
Table 5. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin—2AA (5 mg/L, 1 mg/L)—and the mixture of 2AA with genistein, minerals and combinations.
Tested MixtureG
(Mean ± SD)		IR
(Mean ± SD)		%Anti-Genotox.
Negative Control1.00 ± 0.071.00 ± 0.13
2AA 5 mg/L1.02 ± 0.082.17 ± 0.39
Gen1.21 ± 0.171.79 ± 0.2517%
Zn1.08 ± 0.052.20 ± 0.31
Cu1.16 ± 0.141.60 ± 0.2526%
Ca1.19 ± 0.132.36 ± 0.36
Se1.17 ± 0.122.11 ± 0.40
Fe1.07 ± 0.071.87 ± 0.2714%
gen + Zn0.98 ± 0.092.06 ± 0.42
gen + Cu0.98 ± 0.131.48 ± 0.34 a32%
gen + Ca1.07 ± 0.132.02 ± 0.58
gen + Se1.09 ± 0.161.96 ± 0.55
gen + Fe1.09 ± 0.111.69 ± 0.2822%
2AA 1 mg/L1.00 ± 0.072.00 ± 0.53
Gen1.16 ± 0.171.35 ± 0.2332%
Zn1.03 ± 0.081.77 ± 0.42
Cu1.11 ± 0.121.34 ± 0.3033%
Ca1.16 ± 0.101.86 ± 0.44
Se1.18 ± 0.101.79 ± 0.40
Fe1.10 ± 0.061.59 ± 0.2721%
gen + Zn0.92 ± 0.081.89 ± 0.51 a
gen + Cu0.95 ± 0.131.26 ± 0.2137%
gen + Ca1.08 ± 0.141.58 ± 0.2921%
gen + Se1.04 ± 0.181.61 ± 0.34 a19%
gen + Fe1.04 ± 0.131.44 ± 0.3228%
Each value is expressed as mean ± standard deviation from at least 3 independent biological evaluations. Means that are significant different from positive control (2AA) are bolded (p < 0.05). a Significantly different from the effect of genistein (10 μM) without minerals. %anti-genotox. of the tested samples is calculated as the inhibition of IR induced by genotoxin (2AA).
Table
Table 6. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin–2AA (5 mg/L, 1 mg/L)—and the mixture of 2AA with daidzein, equol and the combinations with minerals.
Table 6. Evaluation of anti-genotoxic activity based on G and IR values for the genotoxin–2AA (5 mg/L, 1 mg/L)—and the mixture of 2AA with daidzein, equol and the combinations with minerals.
Tested MixtureG
(Mean ± SD)		IR
(Mean ± SD)		%Anti-Genotox.
Negative Control1.00 ± 0.081.00 ± 0.10
2AA 5 mg/L0.86 ± 0.092.91 ± 0.54
dai0.99 ± 0.132.36 ± 0.4519%
dai + Zn0.89 ± 0.142.56 ± 0.78
dai + Cu0.94 ± 0.151.71 ± 0.28 a41%
dai + Ca0.98 ± 0.172.81 ± 0.66
dai + Se1.03 ± 0.152.49 ± 0.47
dai + Fe1.00 ± 0.122.03 ± 0.3630%
eq1.03 ± 0.092.08 ± 0.3029%
eq + Zn0.96 ± 0.062.19 ± 0.3825%
eq + Cu1.01 ± 0.061.61 ± 0.32 b45%
eq + Ca1.04 ± 0.122.55 ± 0.50 b
eq + Se1.08 ± 0.132.22 ± 0.4024%
eq + Fe0.96 ± 0.131.80 ± 0.24 b38%
2AA 1 mg/L0.92 ± 0.102.37 ± 0.48
dai0.92 ± 0.162.09 ± 0.45
dai + Zn0.88 ± 0.091.93 ± 0.2519%
dai + Cu0.94 ± 0.141.54 ± 0.22 a35%
dai + Ca0.99 ± 0.132.15 ± 0.32
dai + Se1.00 ± 0.152.00 ± 0.31
dai + Fe0.90 ± 0.151.75 ± 0.29 a26%
eq0.99 ± 0.111.58 ± 0.1834%
eq + Zn0.94 ± 0.101.62 ± 0.1732%
eq + Cu1.03 ± 0.091.17 ± 0.14 b51%
eq + Ca1.09 ± 0.101.76 ± 0.23 b26%
eq + Se1.16 ± 0.101.80 ± 0.3824%
eq + Fe1.06 ± 0.061.51 ± 0.2636%
Each value is expressed as mean ± standard deviation from at least 3 independent biological evaluations. Means that are significant different from positive control (2AA) are bolded (p > 0.05). a Significantly different from the effect of daidzein (10 μM) without minerals. b Significantly different from the effect of equol (10 μM) without minerals. %anti-genotox. of the tested samples is calculated as the inhibition of IR induced by genotoxin (2AA).
Table
Table 7. Summary of anti-genotoxic activity of isoflavonoids, minerals and their combinations against metabolically activated promutagen 2AA (5 mg/L; 1 mg/L).
Table 7. Summary of anti-genotoxic activity of isoflavonoids, minerals and their combinations against metabolically activated promutagen 2AA (5 mg/L; 1 mg/L).
Nutrients 14 01225 i002
+—anti-genotoxicty of used compound(s) ≤ 20%; ++—anti-genotoxicty of used compound(s) 21–40%; +++—anti-genotoxicty of used compound(s) ≥ 40%; Green colour—mixtures showing significantly stronger anti-genotoxic activity in comparison to used isoflavonoid (p > 0.05). Red colour—mixtures showing significantly lower anti-genotoxic activity in comparison to used isoflavonoid (p > 0.05); gen—genistein; dai—daidzein; eq—equol.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Stanisławska, I.J.; Figat, R.; Kiss, A.K.; Bobrowska-Korczak, B. Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer. Nutrients 2022, 14, 1225. https://doi.org/10.3390/nu14061225

AMA Style

Stanisławska IJ, Figat R, Kiss AK, Bobrowska-Korczak B. Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer. Nutrients. 2022; 14(6):1225. https://doi.org/10.3390/nu14061225

Chicago/Turabian Style

Stanisławska, Iwona J., Ramona Figat, Anna K. Kiss, and Barbara Bobrowska-Korczak. 2022. "Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer" Nutrients 14, no. 6: 1225. https://doi.org/10.3390/nu14061225

APA Style

Stanisławska, I. J., Figat, R., Kiss, A. K., & Bobrowska-Korczak, B. (2022). Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer. Nutrients, 14(6), 1225. https://doi.org/10.3390/nu14061225

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop